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Abstract
Background: Artemisinin combination therapy has become the standard of care for uncomplicated malaria in
most of Africa. However, there is limited data on the safety and tolerability of these drugs, especially in young
children and patients co-infected with HIV.
Methods: A longitudinal, randomized controlled trial was conducted in a cohort of HIV-infected and uninfected
children aged 4-22 months in Tororo, Uganda. Participants were randomized to treatment with artemether-
lumefantrine (AL) or dihydroartemisinin-piperaquine (DP) upon diagnosis of their first episode of uncomplicated
malaria and received the same regimen for all subsequent episodes. Participants were actively monitored for
adverse events for 28 days and then passively for up to 63 days after treatment. This study was registered in
ClinicalTrials.gov (registration # NCT00527800).
Results: A total of 122 children were randomized to AL and 124 to DP, resulting in 412 and 425 treatments,
respectively. Most adverse events were rare, with only cough, diarrhoea, vomiting, and anaemia occurring in more
than 1% of treatments. There were no differences in the risk of these events between treatment groups. Younger
age was associated with an increased risk of diarrhoea in both the AL and DP treatment arms. Retreatment for
malaria within 17-28 days was associated with an increased risk of vomiting in the DP treatment arm (HR = 6.47,
95% CI 2.31-18.1, p < 0.001). There was no increase in the risk of diarrhoea or vomiting for children who were
HIV-infected or on concomitant therapy with antiretrovirals or trimethoprim-sulphamethoxazole prophylaxis.
Conclusion: Both AL and DP were safe and well tolerated for the treatment of uncomplicated malaria in young
HIV-infected and uninfected children.
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Background
Guidelines for the treatment of uncomplicated malaria in
Africa have recently undergone a paradigm shift away
from inexpensive monotherapies, such as chloroquine
and sulphadoxine-pyrimethamine, to artemisinin-based
combination therapies (ACT). Two of the most important
artemisinin-based combinations for use in Africa are arte-
mether-lumefantrine (AL) and dihydroartemisinin-piper-
aquine (DP). AL has been shown to be highly efficacious
and well tolerated, and has become the most widely rec-
ommended first-line regimen in Africa [1,2]. DP, a newer
ACT, has shown excellent efficacy in multiple trials from
Asia and Africa and is considered a highly promising drug
for global deployment due to its simple once-a-day dosing
and extended post-treatment prophylactic effect [3-7].
Although ACT has been shown to be highly efficacious,
concerns remain about its safety and tolerability, espe-
cially in certain patient populations, such as young chil-
dren and those with co-morbidities such as HIV.
There are a number of methodological challenges in eval-
uating the safety of anti-malarial drugs, such as establish-
ing causality between drugs and adverse events in the
setting of malaria. The World Health Organization
(WHO) has established guidelines for evaluating the effi-
cacy of anti-malarial drugs, but no similar guidelines exist
for safety monitoring [8-10]. A lack of uniformly applied
methods for adverse events reporting limits the ability to
compare data from different studies. Additionally, most
anti-malarial safety data come from clinical trials evaluat-
ing single episodes of malaria, while in practice African
children are often treated repeatedly for recurring epi-
sodes of malaria over a relatively short period of time.
Despite these challenges, comparative data on the safety
and tolerability of different forms of ACT are critical for
making informed policy decisions.
Results of a study comparing the efficacy AL and DP for
the treatment of uncomplicated malaria using a longitudi-
nal study design in a cohort of young children living in an
area of very high malaria transmission intensity in
Uganda were recently published [11]. This cohort
included HIV-unexposed (HIV-uninfected children born
to HIV-uninfected mothers), HIV-exposed (HIV-unin-
fected children born to HIV-infected mothers), and HIV-
infected infants enrolled from six weeks to 12 months of
age and followed up to one year. Results presented here
include detailed data on the safety and tolerability of
these therapies with follow-up extended for two addi-
tional months, in the context of repeated treatments, HIV
co-infection, and the concomitant use of trimethoprim-
sulphamethoxazole (TS) prophylaxis and anti-retroviral
(ARV) therapy.
Methods
Study site and subjects
This study was conducted in Tororo, a rural district in
southeast Uganda, where malaria is holoendemic [12].
Participants were drawn from a cohort of HIV-unexposed,
HIV-exposed, and HIV-infected children, enrolled
between August 2007 and April 2008 using convenience
sampling. Eligibility criteria included: (1) age six weeks to
twelve months at enrollment; (2) documented HIV status
of mother and child; (3) agreement to receive all medical
care at the study clinic; (4) agreement to avoid medication
administered outside the study; and (5) no history of
allergies to AL or DP. All study participants were given a
long-lasting insecticide-treated bed net (ITN) at enroll-
ment. Daily TS prophylaxis was given to all HIV-infected
and HIV-exposed participants, as per national guidelines.
ARV therapy (nevirapine + lamivudine + zidovudine or
stavudine) was provided to all HIV-infected participants
meeting standardized WHO criteria. The study protocol
was approved by the Uganda National Council of Science
and Technology and the institutional review boards of the
University of California, San Francisco, Makerere Univer-
sity, the University of Washington, and the Centers for
Disease Control and Prevention.
Follow-up of study participants, malaria diagnosis and 
treatment
Details of the study procedures have been published pre-
viously and are summarized here [11]. Study participants
were followed for all of their health needs in a dedicated
study clinic. Children presenting with new medical prob-
lems underwent standardized evaluation. Subjects who
presented with fever had blood obtained by fingerprick
for a thick blood smear. If the thick blood smear was pos-
itive, the patient was diagnosed with malaria. Study par-
ticipants  ≥4 months of age and weighing ≥5 kg were
randomly assigned to receive either open label AL or DP
at the time their first episode of uncomplicated malaria
was diagnosed. Study participants received the same treat-
ment regimen for all subsequent episodes of uncompli-
cated malaria diagnosed during the study.
Study drugs were administered according to weight-based
guidelines for fractions of tablets as follows: AL (Coar-
tem®, Novartis, 20 mg artemether/120 mg lumefantrine
tablets), administered as one (5-14 kg) or two (15-24 kg)
tablets given twice daily for three days; DP (Duocotecxin®,
Holley Pharm, 40 mg dihydroartemisinin/320 mg piper-
aquine tablets), targeting a total dose of 6.4 and 51.2 mg/
kg of dihydroartemisinin and piperaquine, respectively,
given in three equally divided daily doses to the nearest 1/
4 tablet.Malaria Journal 2009, 8:272 http://www.malariajournal.com/content/8/1/272
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Definitions of adverse events
Participants randomized to treatment with study medica-
tions were assessed for adverse events beginning after their
first dose of study drug. An adverse event was defined as
any untoward medical occurrence, irrespective of its sus-
pected relationship to the study medications as per Inter-
national Conference of Harmonization (ICH) guidelines
[13] and graded according to severity (mild, moderate,
severe, life threatening). A pre-determined list of 43
adverse events and standardized definitions was devel-
oped using the United States National Institutes of
Health, Division of AIDS Table for Grading the Severity of
Adult and Pediatric Adverse Events [14]. A serious adverse
event was defined as any adverse experience that resulted
in death, life threatening experience, participant hospital-
ization, persistent or significant disability or incapacity, or
specific medical or surgical intervention to prevent serious
outcome.
Active and passive surveillance for adverse events
On the day that treatment was initiated (day 0), a baseline
assessment was conducted, consisting of a standardized
history and physical examination and haemoglobin
measurement using a portable spectrophotometer
(Hemocue, Angelholm Sweden). Active surveillance for
adverse events following therapy consisted of assessment
on days 1, 2, 3, 7, 14, 21, 28 and any other day they felt
ill. Haemoglobin measurements were repeated on day 28
or earlier if severe anaemia was suspected. At each follow-
up visit, adverse events were identified by evaluating for
any new or worsening symptoms, physical exam findings,
or haemoglobin values, as compared to the day 0 baseline
assessment. Participants with abnormalities present on
day 0 were not classified as experiencing an adverse event
unless the symptom worsened from baseline, or resolved
and then recurred. Following the initial 28-day active sur-
veillance period, participants were asked to return to the
clinic only when they desired medical attention. Passive
surveillance for adverse events continued until the partic-
ipant was re-treated with study drugs (at which time a new
cycle of adverse event assessment began), the end of the
study period (September 2008), or withdrawal from the
study.
Statistical analysis
Data were double entered into Microsoft Access and ana-
lysed using Stata version 10 (Stata, College Station, TX,
USA). Data were evaluated with an intention-to-treat
analysis including all episodes of uncomplicated malaria
in children who were assigned treatment with study drugs
through September 2008. The cumulative risks of the first
occurrence of individual adverse events following the ini-
tiation of study drug therapy were estimated using the
Kaplan-Meier product limit formula. Participants were
censored on the day prior to repeat therapy with study
drugs to remove the potential confounding effect of recur-
rent malaria, which can mimic adverse events [15].
Cumulative risks were estimated over the following pre-
specified time intervals following the initiation of ther-
apy; days 1-3 and 4-28 during active surveillance and days
29-63 during passive surveillance considering only
patients who were at risk during these time intervals. Anal-
ysis of adverse events during passive surveillance was lim-
ited to 63 days because this is typically the longest
duration of follow-up used in anti-malarial clinical trials
and likely captures the majority of adverse events causally
related to study drugs [11]. The risks of individual adverse
events between treatment arms were compared using Cox
proportional hazard models, adjusting for repeated treat-
ments for malaria in the same patient.
Multivariate Cox proportional hazards models were used
to measure the associations between the following covari-
ates and the risk of common adverse events after 28 days
of follow-up, adjusting for repeated measures in the same
patient: 1) age, 2) duration since last treatment with study
drugs, and 3) combination of HIV status, concomitant TS
use and ARV use. Comparisons of adverse events due to
anaemia after 28 days of follow-up were modeled with a
binomial distribution using generalized estimating equa-
tions, adjusting for repeated measures in the same study
participant with exchangeable correlation and robust
standard errors. A p-value < 0.05 was considered statisti-
cally significant.
Results
Patient population and characteristics of study drug 
treatments
A total of 351 children were enrolled in the cohort study,
of which 246 (70%) had at least one episode of uncom-
plicated malaria and were randomized to study drugs. A
total of 122 children were randomized to AL resulting in
412 treatments and 124 children were randomized to DP
resulting in 425 treatments (Figure 1). Overall, 54% of the
study drug treatments were given in children one year of
age or younger, 38% of patients were taking TS concomi-
tantly, 10% of patients were HIV infected, and 8% of
patients were taking ARVs concomitantly (Table 1). Con-
sidering 28-day outcomes, 715 (85%) completed follow-
up without recurrent malaria, 106 (13%) had recurrent
malaria, and 16 (2%) had incomplete follow-up. Patients
treated with AL were more likely to have been treated with
study drugs in the previous 28 days compared to those
treated with DP (18% vs. 4%) (Table 1). When follow-up
was extended to 63 days, 492 (59%) patients had recur-
rent malaria, with no difference observed between those
treated with AL and those treated with DP.Malaria Journal 2009, 8:272 http://www.malariajournal.com/content/8/1/272
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Comparison of risks for clinical adverse events between 
study drugs
Among the list of 42 clinical adverse events that were
included in our standardized assessment, 32 were not
reported, 7 (dyspnea, dysphagia, jaundice, malaise, rash,
seizure, and weight-loss) occurred in less than 1% of study
drug treatments, and 3 (cough, diarrhoea, and vomiting)
were frequent enough for comparative analyses. Consid-
ering 63 days of follow-up among all 837 treatments with
study drugs; 415 adverse events due to cough (373 mild
and 42 moderate severity), 179 adverse events due to diar-
rhoea (168 mild, 10 moderate, and one severe), and 56
adverse events due to vomiting (all mild) were reported.
Any adverse event due to cough, diarrhoea, or vomiting
occurred in 296 of 412 (72%) treatments with AL and 313
of 425 (74%) treatments with DP. Comparisons of the
risks for the three most common adverse events between
the AL and DP treatment arms after 1-3, 4-28, and 29-63
days of follow-up are presented in Table 2. There were no
statistically significant differences in the risks of these
adverse events between the treatment arms for any time
interval.
Other risk factors for clinical adverse events
Non-treatment related risk factors for diarrhoea and vom-
iting over 28 days of follow-up stratified by treatment
group were identified using multivariate analysis (Table
3). Risk factors of interest included age, duration since last
treatment with study drugs, HIV status, concomitant TS
use, and concomitant ARV use. Adverse events due to
cough were not included in this analysis because this
adverse event was unlikely to be causally related to anti-
malarial therapy based on previous reports [3-7]. Younger
age was associated with an increased risk of diarrhoea, but
not vomiting, in both the AL and DP treatment arms.
Repeat therapy within 17-28 days was associated with an
increased risk of vomiting in the DP treatment arm (HR =
6.47, 95% CI 2.31-18.1, p < 0.001), but not the AL treat-
ment arm. Among HIV-uninfected patients, there was no
association between concomitant use of TS and the risk of
diarrhoea or vomiting for both treatment arms. The inde-
pendent effects of HIV in the absence of TS or ARV use
could not be evaluated due to the small number of obser-
vations. Compared to HIV-uninfected not taking TS, con-
comitant use of TS and ARVs among HIV-infected patients
was not associated with an increased risk of diarrhoea or
vomiting in either treatment arm.
Risk of adverse events due to anaemia and serious adverse 
events
Among 837 treatments with study drugs, 107 (13%)
repeat haemoglobin measurements were made on the day
of recurrent malaria and 8 (1%) had missing repeat hae-
moglobin measurements and were not included in the
analysis of adverse events due to anaemia. There was no
significant difference in the risks of adverse events due to
anaemia in the AL and DP treatment arms (10% vs. 14%,
p = 0.09).
Serious adverse events were rare. Out of 837 total treat-
ments with study drugs, there were only 5 serious adverse
events (two in the AL group and three in the DP group)
and all were due to the development of severe anaemia,
which was likely a consequence of malaria and not the
study drugs. Of note, one patient developed severe anae-
mia twice following treatment with DP. This patient was
removed from the study protocol because of initial con-
cerns about a causal relationship between DP and severe
anaemia. However, the patient developed a subsequent
episode of malaria off-protocol that was treated with AL,
Table 1: Baseline characteristics of all episodes of uncomplicated malaria treated with study drugs
Characteristic Treatment Group
AL (n = 412) DP (n = 425)
Treatment episodes per child, median (range) 2 (1-11) 2 (1-9)
Age at time of treatment in months, mean (SD) 12.5 (3.6) 12.6 (3.8)
4-10 months, n (%) 104 (25%) 118 (28%)
>10-12 months, n (%) 111 (27%) 114 (27%)
>12-15 months, n (%) 85 (21%) 78 (18%)
>15-22 months, n (%) 112 (27%) 115 (27%)
HIV status, TS use, ARV use
HIV-uninfected not taking TS, n (%) 248 (60%) 271 (64%)
HIV-uninfected taking TS, n (%) 115 (28%) 121 (28%)
HIV-infected only taking TS, n (%) 8 (1.9%) 8 (1.9%)
HIV-infected taking TS and ARVs, n (%) 41 (10%) 25 (5.9%)
Duration since last study drug treatment
17 - 28 days, n (%) 76 (18%) 18 (4.2%)
28 - 63 days, n (%) 146 (35%) 192 (45%)
>63 days or no prior treatment, n (%) 190 (46%) 215 (51%)Malaria Journal 2009, 8:272 http://www.malariajournal.com/content/8/1/272
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and again developed severe anaemia, which resulted in
his death. A blood sample taken during the anemic epi-
sode in the month prior to his death was direct Coombs
test positive, indicative of immune-mediated haemolytic
anaemia. Post-mortem this male child was found to be
hemizygous for the G202A mutation, the predominant
East African allele of glucose-6-phosphate dehydrogenase
deficiency.
Discussion
Results from this longitudinal randomized clinical trial
suggest that both AL and DP are safe for treating uncom-
plicated malaria in young HIV-infected and uninfected
infants and children. Adverse events were uncommon and
generally of mild severity, with only cough, diarrhoea,
vomiting, and anaemia occurring in more than 1% of
treatments with study drugs. There were no significant dif-
ferences in adverse events between the two treatment
arms, although recent treatment with DP was associated
with an increased risk of vomiting. Concomitant use of TS
and ARVs were not associated with an increased risk of
common adverse events.
This study contributes to a body of literature suggesting
that AL and DP are both safe and well tolerated across a
wide range of epidemiological settings. AL has been exten-
sively studied in clinical trials primarily from Asia and
Africa, and was added to the WHO Essential Medicines
List in 2002. A review of AL safety and tolerability in 1,869
patients (33% children) from Asia reported gastro-intesti-
nal complaints (nausea, vomiting, and diarrhoea), head-
ache, and dizziness as the most commonly reported
adverse events [16]. Several randomized clinical trials
from Africa have reported adverse events associated with
AL similar to those from Asia, with safety and tolerability
profile found to be equivalent or superior to comparator
regimens such as amodiaquine + sulphadoxine-pyrimeth-
amine or amodiaquine + artesunate [17-22]. DP has also
been shown to be very safe and well tolerated in studies
from Asia and Africa. In a review of 2,600 patients from
studies primarily done in Asia, gastrointestinal com-
plaints were the most common adverse events associated
with DP, with no evidence of severe drug toxicity [5]. In
three clinical trials comparing AL (n = 597) versus DP (n
= 613) in Africa using similar protocols, the risks of
adverse events between these two treatment groups were
similar [3,6,7]. In these studies a total of 13 serious
adverse events (1.1%) were reported (AL = 4, DP = 9), and
all were felt to be unrelated to the study drugs. The most
severe adverse event in this trial, death due to presumed
Trial profile Figure 1
Trial profile. Enrollment and randomization of study patients.
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          131 HIV-exposed 
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Table 2: Risk of common adverse events for discrete time periods following initiation of therapy
Time interval Treatment 
arm
Adverse event
Cough Diarrhoea Vomiting
Risk* HR† (95% CI) p-value Risk* HR† (95% CI) p-value Risk* HR† (95% CI) p-value
1-3 days AL 7.8% 1.14 (0.71-1.84) 0.59 4.1% 1.13 (0.59-2.19) 0.71 1.2% 1.36 (0.41-4.44) 0.61
DP 8.9% 4.7% 1.7%
4-28 days AL 39.8% 1.17 (0.93-1.48) 0.18 18.5% 0.81 (0.57-1.15) 0.23 2.1% 2.10 (0.92-4.79) 0.08
DP 47.1% 15.1% 4.4%
28-63 days AL 51.9% 0.99 (0.68-1.46) 0.97 22.1% 0.90 (0.53-1.53) 0.70 11.6% 0.70 (0.34-1.43) 0.33
DP 47.1% 18.9% 7.4%
* Cumulative risk during time interval of interest estimated using the Kaplan-Meier product limit formula
† HR = hazard ratio for DP vs. AL, generated using multivariate Cox proportional hazard models adjusted for repeated measures in the same 
patient
Table 3: Risk factors for adverse events due to diarrhoea or vomiting within 28 days following therapy
Risk category Risk group Diarrhoea Vomiting
AL DP AL DP
HR† 
(95% CI)
p-value HR† 
(95% CI)
p-value HR† 
(95% CI)
p-value HR† 
(95% CI)
p-value
Age >15-22 months 1.0 
(reference)
- 1.0 
(reference)
- 1.0 
(reference)
- 1.0 
(reference)
-
>12-15 months 1.17 
(0.56-2.46)
0.67 3.34 
(1.39-8.02)
0.007 0.75 
(0.10-5.58)
0.78 2.66 
(0.80-8.85)
0.11
>10-12 months 2.04 
(1.09-3.85)
0.03 4.03 
(1.90-8.53)
< 0.001 0.32 
(0.04-2.86)
0.31 2.61 
(0.66-10.3)
0.17
4-10 months 2.11 
(1.09-4.08)
0.03 3.22 
(1.33-7.81)
0.01 1.14 
(0.30-4.27)
0.84 1.08 
(0.20-5.90)
0.93
Duration since 
last treatment
> 63 days or no 
prior treatment
1.0 
(reference)
- 1.0 
(reference)
- 1.0 
(reference)
- 1.0 
(reference)
-
28-63 days 0.54 
(0.34-0.86)
0.009 0.85 
(0.47-1.52)
0.57 0.77 
(0.24-2.42)
0.65 0.78 
(0.30-2.02)
0.60
17-28 days 0.68 
(0.36-1.29)
0.24 1.33 
(0.47-3.73)
0.59 0.71 
(0.11-4.73)
0.72 6.63 
(2.33-18.9)
< 0.001
HIV status, HIV-uninfected 
not taking TS
1.0 
(reference)
- 1.0 
(reference)
- 1.0 
(reference)
- 1.0 
(reference)
-
TS use, HIV-uninfected 
taking TS
0.78 
(0.47-1.28)
0.32 1.26 
(0.76-2.11)
0.37 1.04 
(0.27-4.02)
0.95 1.30 
(0.47-3.55)
0.62
ARV use* HIV-infected 
taking TS and 
ARVs
0.33 
(0.12-0.90)
0.03 0.46 
(0.11-2.03)
0.31 1.77 
(0.20-15.7)
0.61 1.85 
(0.31-10.9)
0.50
† HR = hazard ratio, generated using multivariate Cox proportional hazard models adjusted for repeated measures in the same patient
* HIV-infected patients not taking ARVs not included in the analysis due to small numbers (n = 16)Malaria Journal 2009, 8:272 http://www.malariajournal.com/content/8/1/272
Page 7 of 8
(page number not for citation purposes)
haemolytic anaemia, occurred in a child found to have
G6PD deficiency. Haemolysis following treatment with
DP in a child with G6PD deficiency has been described in
a prior study from Laos [23]. However, it is unclear
whether haemolytic anaemia is causally associated with
DP or just a consequence of G6PD deficiency alone [23].
This study addresses some of the limitations from previ-
ously published studies on the safety and tolerability of
AL and DP. First there is limited data on the safety of these
drugs in children under 12 months of age, an important
population in Africa. Study participants initiated ACT
therapy at four months of age and over 50% of the treat-
ments given for uncomplicated malaria were in children
younger than 12 months. Both medications were well tol-
erated by infants, with diarrhoea the only adverse event
associated with this younger age group, independent of
the treatment given. Second, most anti-malarial clinical
trials are limited to single episodes of uncomplicated
malaria in the same patient, which precludes the ability to
analyse the effect of repeated treatments. The longitudinal
design used in this study allowed for the follow-up of chil-
dren for up to one year, and observe the effects of repeated
treatments of ACT drugs. Repeated therapy was found to
be generally safe and well tolerated with the exception of
a significantly higher risk of vomiting following repeat
treatment with DP within 2-4 weeks of a previous dose.
Although the extended half-life of piperaquine [24] pro-
vides a prolonged post-treatment prophylactic effect
[3,6,7], repeat therapy with DP over a short period of time
may increase the risk of adverse events and should be
investigated further. This study also provides data on the
safety and tolerability of ACT in unique patient popula-
tions including those taking TS prophylaxis and HIV-
infected patients taking ARVs. Almost 40% of the patients
were concomitantly taking TS when treated for malaria,
however, this was not associated with an increased risk of
adverse events. The concomitant use of ARVs and ACT is
of greater concern because drug toxicities and the poten-
tial for drug interactions [25]. Artemether is metabolized
via CYP3A4 to the more active compound dihydroartem-
isinin. Lumefantrine is also metabolized by CYP3A4. Less
is known about the metabolism of piperaquine. There are
three main classes of ARVs: protease inhibitors (PIs), non-
nucleoside reverse transcriptase inhibitors (NNRTIs), and
nucleoside reverse transcriptase inhibitors (NRTIs). PIs
can be either potent inducers or inhibitors of CYP3A4. In
a study of healthy subjects the PI lopinavir/ritonavir
increased the lumefantrine area under the curve (AUC) by
193%, though no significant toxicities were reported [26].
NNRTIs can also be inducers or inhibitors of CYP3A4 with
efavirenz primarily inhibiting CYP3A4 and nevirapine
primarily inducing CYP3A4. Nucleoside reverse tran-
scriptase inhibitors (NRTIs) are not thought to have clini-
cal significant interactions with commonly used ACTs
[25]. Prior studies have found an association between
amodiaquine-based anti-malarial therapy and neutropae-
nia in HIV-infected children [27]. In this study, no associ-
ation between the risk of adverse events and the
concomitant use of ARVs was found. However, this study
had a limited number of patients taking ARVs (n = 66),
and only included NNRTI + NRTI containing regimens.
There were several limitations to this study. Firstly,
although every effort was made to apply standardized def-
initions for adverse events, treatment assignment was not
blinded and results were limited by largely subjective
reports of symptoms from parents or guardians. Secondly,
only haemoglobin levels were regularly measured during
the period of malaria follow-up, preventing the detection
other laboratory associated adverse events. Finally, this
study was not powered to specifically test for hypothesis
of differences in the risk of adverse events between the var-
ious subgroups. Therefore, the possibility of type II errors
cannot be ruled out, especially in those subgroups with
small samples sizes such as HIV-infected children taking
ARVs.
Conclusion
In summary, both AL and DP were safe and well tolerated
for the treatment of uncomplicated malaria in a cohort of
children uniquely characterized by their young age,
repeated therapy, and the inclusion of HIV-exposed and
HIV-infected patients. However, the occurrence of haemo-
lytic anaemia leading to death in a G6PD deficient patient
highlights the importance of monitoring for rare, but seri-
ous adverse events. As the use of ACT is scaled up in Africa,
continued evaluation of the safety and tolerability of these
drugs in diverse patient populations is essential.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
GD and EA supervised the clinical studies. SK and GD
analysed the data. All authors contributed to the drafting
of the manuscript.
Acknowledgements
We thank the clinical study team and our administrative staff. We are grate-
ful to the children who participated in this study, and to their parents and 
guardians.
The study received financial support from the Doris Duke Charitable Foun-
dation (GD is a recipient of the Clinical Scientist Development Award) and 
the Centers for Disease Control and Prevention Global AIDS Program. 
Dihydroartemisinin-piperaquine study drugs were provided free of charge 
by Holleypharm, China. The funders had no involvement in the study 
design, data collection, data analysis, data interpretation, in the writing of 
the manuscript, or in the decision to submit it for publication. TS was sup-
ported in part by a pilot grant from the Puget Sound Partners in Global 
Health.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2009, 8:272 http://www.malariajournal.com/content/8/1/272
Page 8 of 8
(page number not for citation purposes)
References
1. Bosman A, Mendis K: A major transition in malaria treatment:
The adoption and deployment of artemisinin-based combi-
nation therapies.  Am J Trop Med Hyg 2007, 77:193-197.
2. World Health Organization (WHO): Global AMDP Database-AFRO
2008 [http://www.who.int/malaria/amdp/amdp_afro.htm]. Accessed
December 7, 2008
3. Kamya MR, Yeka A, Bukirwa H, Lugemwa M, Rwakimari JB, Staedke
SG, Talisuna AO, Greenhouse B, Nosten F, Rosenthal PJ, Wabwire-
Mangen F, Dorsey G: Artemether-lumefantrine versus dihy-
droartemisinin-piperaquine for treatment of malaria: A ran-
domized trial.  PLoS Clin Trials 2007, 2:e20.
4. Karema C, Fanello CI, van Overmeir C, van Geertruyden JP, van
Doren W, Ngamije D, D'Alessandro U: Safety and efficacy of
dihydroartemisinin/piperaquine (Artekin) for the treatment
of uncomplicated Plasmodium falciparum malaria in Rwandan
children.  Trans R Soc Trop Med Hyg 2006, 100:1105-11.
5. Myint HY, Ashley EA, Day NP, Nosten F, White NJ: Efficacy and
safety of dihydroartemisinin-piperaquine.  Trans R Soc Trop Med
Hyg 2007, 101:858-66.
6. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB,
Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H: Arte-
mether-lumefantrine versus dihydroartemisinin-piper-
aquine for treating uncomplicated malaria: A randomized
trial to guide policy in Uganda.  PLoS ONE 2008, 3:e2390.
7. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ,
Ouédraogo JB: Randomized comparison of amodiaquine plus
sulfadoxine-pyrimethamine, artemether-lumefantrine, and
dihydroartemisinin-piperaquine for the treatment of
uncomplicated  Plasmodium falciparum malaria in Burkina
Faso.  Clin Infect Dis 2007, 45:1453-61.
8. World Health Organization (WHO): Susceptibility of Plasmodium
falciparum to antimalarial drugs: Report on global monitor-
ing 1996-2004.  Geneva 2005.
9. Talisuna AO, Staedke SG, D'Alessandro U: Pharmacovigilance of
antimalarial treatment in Africa: Is it possible?  Malar J 2006,
5:50.
10. Mehta U, Durrheim D, Mabuza A, Blumberg L, Allen E, Barnes KI:
Malaria pharmacovigilance in Africa: Lessons from a pilot
project in Mpumalanga province, South Africa.  Drug Saf 2007,
30:899-910.
11. Arinaitwe E, Sandison TG, Wanzira H, Kakuru A, Homsy J, Kalamya J,
Kamya MR, Vora N, Greenhouse B, Rosenthal PJ, Tappero J, Dorsey
G: Artemether-lumefantrine versus dihydroartemisinin-pip-
eraquine for falciparum malaria: Longitudinal randomized
trial in HIV-infected and uninfected children.  Clin Infect Dis
2009, 49:1629-37.
12. Okello PE, Van Bortel W, Byaruhanga AM, Correwyn A, Roelants P,
Talisuna A, D'Alessandro U, Coosemans M: Variation in malaria
transmission intensity in seven sites throughout Uganda.  Am
J Trop Med Hyg 2006, 75:219-25.
13. International Conference on Harmonisation (ICH). ICH harmonised
tripartite guideline: Clinical safety data management: Defini-
tions and standards for expedited reporting E2A.  Technical
Document, ICH 1994.
14. Division of microbiology and infectious diseases, National Institute of
Allergy and Infectious Diseases, National Institutes of Health: Pedi-
atric toxicity tables.  2001 [http://www3.niaid.nih.gov/NR/rdon
lyres/B7B341E5-2F99-4449-AABA-384B2BAD0E19/0/dmidped-
tox.doc]. Accessed April 10, 2008
15. Staedke SG, Jagannathan P, Yeka A, Bukirwa H, Banek K, Maiteki-
Sebuguzi C, Clark TD, Nzarubara B, Njama-Meya D, Mpimbaza A,
Rosenthal PJ, Kamya MR, Wabwire-Mangen F, Dorsey G, Talisuna
AO: Monitoring antimalarial safety and tolerability in clinical
trials: A case study from Uganda.  Malar J 2008, 7:107.
16. Bakshi R, Hermeling-Fritz I, Gathmann I, Alteri E: An integrated
assessment of the clinical safety of artemether-lumefantrine:
A new oral fixed-dose combination antimalarial drug.  Trans
R Soc Trop Med Hyg 2000, 94:419-24.
17. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley
C, Greenwood BM, Whitty CJ: Amodiaquine alone, amodi-
aquine+sulfadoxine-pyrimethamine, amodiaquine+artesu-
nate, and artemether-lumefantrine for outpatient
treatment of malaria in Tanzanian children: A four-arm ran-
domised effectiveness trial.  Lancet 2005, 365:1474-80.
18. Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N,
Rwakimari JB, Rosenthal PJ, Wabwire-Mangen F, Dorsey G, Staedke
SG:  Artemisinin combination therapies for treatment of
uncomplicated malaria in Uganda.  PLoS Clin Trials 2006, 1:e7.
19. Fanello CI, Karema C, van Doren W, Van Overmeir C, Ngamije D,
D'Alessandro U: A randomised trial to assess the safety and
efficacy of artemether-lumefantrine (Coartem) for the
treatment of uncomplicated Plasmodium falciparum malaria
in Rwanda.  Trans R Soc Trop Med Hyg 2007, 101:344-50.
20. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B,
Maiteki-Sebuguzi C, Dokomajilar C, Kamya MR, Rosenthal PJ: Com-
bination therapy for uncomplicated falciparum  malaria in
Ugandan children: A randomized trial.  JAMA 2007, 297:2210-9.
21. Maiteki-Sebuguzi C, Jagannathan P, Yau VM, Clark TD, Njama-Meya
D, Nzarubara B, Talisuna AO, Kamya MR, Rosenthal PJ, Dorsey G,
Staedke SG: Safety and tolerability of combination antimalar-
ial therapies for uncomplicated falciparum malaria in Ugan-
dan children.  Malar J 2008, 7:106.
22. Omari AA, Gamble C, Garner P: Artemether-lumefantrine (six-
dose regimen) for treating uncomplicated falciparum
malaria.  Cochrane Database Syst Rev 2005, 4:CD005564.
23. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N, Barends
M, Keola S, Pongvongsa T, Phompida S, Phetsouvanh R, Stepniewska
K, White NJ, Newton PN: An open, randomized comparison of
artesunate plus mefloquine vs. dihydroartemisinin-piper-
aquine for the treatment of uncomplicated Plasmodium falci-
parum  malaria in the Lao People's Democratic Republic
(Laos).  Trop Med Int Health 2006, 11:1157-65.
24. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L, Day
NP, McGready R, Ashton M, Nosten F, White NJ: Population phar-
macokinetics of piperaquine after two different treatment
regimens with dihydroartemisinin-piperaquine in patients
with Plasmodium falciparum malaria in Thailand.  Antimicrob
Agents Chemother 2008, 52:1052-61.
25. Dooley KE, Flexner C, Andrade AS: Drug interactions involving
combination antiretroviral therapy and other anti-infective
agents: Repercussions for resource-limited countries.  J Infect
Dis 2008, 198:948-61.
26. German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D,
Charlebois E, Hanpithakpong W, Lindegardh N, Aweeka FT: Lopina-
vir/ritonavir affects pharmacokinetic exposure of arte-
mether/lumefantrine in HIV-uninfected healthy volunteers.
J Acquir Immune Defic Syndr 2009, 51:424-9.
27. Gasasira AF, Kamya MR, Achan J, Mebrahtu T, Kalyango JN, Ruel T,
Charlebois E, Staedke SG, Kekitiinwa A, Rosenthal PJ, Havlir D, Dor-
sey G: High risk of neutropenia in HIV-infected children fol-
lowing treatment with artesunate plus amodiaquine for
uncomplicated malaria in Uganda.  Clin Infect Dis 2008,
46:985-91.